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reduction in endotoxaemia. We aimed to test the effect of this
device on survival in a pig model of acetaminophen-induced
acute liver failure.
Methods: Pigs were randomised to three groups: Acetaminophen
plus University College London-Liver Dialysis Device (n = 9);
Acetaminophen plus Control Device (n = 7); and Control plus
Control Device (n = 4). Device treatment was initiated two h after
onset of irreversible acute liver failure.
Results: The Liver Dialysis Device resulted in 67% reduced risk of
death in acetaminophen-induced acute liver failure compared to
Control Device (hazard ratio = 0.33, p = 0.0439). This was associ-
ated with 27% decrease in circulating irreversibly oxidised human
non-mercaptalbumin-2 throughout treatment (p = 0.046); 54%
reduction in overall severity of endotoxaemia (p = 0.024); delay
in development of vasoplegia and acute lung injury; and delay
in systemic activation of the TLR4 signalling pathway. Liver
Dialysis Device-associated adverse clinical effects were not seen.
Conclusions: The survival benefit and lack of adverse effects
would support clinical trials of University College London-Liver
Dialysis Device in acute liver failure patients.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY license.Introduction
Liver transplantation (LT) is the only treatment proven to prolong
survival in patients with acute liver failure (ALF), who fulfil crite-
ria for poor prognosis, but LT remains a limited resource with
alternative therapies being an unmet need [1]. In ALF, severity
of liver injury and clinical progression of disease is in part conse-
quent upon activation of the innate immune system [2–5].
Endotoxaemia in ALF contributes to this innate immune response
[6]. Moreover in liver failure, the detoxifying function of albumin,15 vol. 63 j 634–642
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which is critical to recovery from liver injury, is irreversibly
destroyed [7,8].
Acetaminophen (APAP) overdose is the leading cause of ALF in
the UK and USA [1,9]. APAP toxicity results from its hepatic meta-
bolism into toxic N-acetyl-p-benzoquinone imine (NAPQI).
Subsequent formation of harmful NAPQI protein adducts causes
mitochondrial oxidant stress and ultimately hepatocyte death
[4]. However the severity of the ensuing liver injury and clinical
syndrome of ALF is exacerbated by activation of the innate
immune system by damage-associated molecular patterns
(DAMPs) released by dying hepatocytes and likely other resident
cells of the liver [3,5]. DAMPs implicated in ALF include
high-mobility group box-1 protein (HMGB1), heat shock protein
70 and deoxyribonucleic acid (DNA) fragments [10–12]. HMGB1
has been shown to act via the toll-like receptor 4 (TLR4) pathway
to exacerbate immune response [12–14] and DNA fragments may
contribute to activation of the nacht, leucine-rich repeat and
pyrin domain-containing protein 3 (Nalp3) inflammasome and
subsequent activation of pro-inflammatory cytokines,
Interleukin-1b (IL-1b) and IL-18 [11].
Endotoxin or lipopolysaccharide, a component of the cell wall
of gram-negative bacteria, has been described as a ‘‘cofactor’’ in
APAP-induced liver injury [6]. The liver plays a critical role in
clearance of gut-derived endotoxin, which may or may not be
associated with viable gram-negative bacteria. Data from
APAP-induced rodent models of ALF suggest that endotoxin stim-
ulates the innate immune response and produces liver injury
through activation of hepatic Kupffer cells to increase
pro-inflammatory cytokine production [14,15].
Albumin is the most abundant plasma protein and is synthe-
sized in the liver. Besides maintaining plasma oncotic pressure, it
also serves many detoxification, immune and circulatory functions
[16]. Human serum albumin (HSA) infusion has been shown to
reduce mortality in liver failure patients with spontaneous bacte-
rial peritonitis and hepatorenal syndrome and following large vol-
ume paracentesis [16]. Molecular Adsorbent Recirculating System
(MARS) is an extracorporeal liver assist device, based on the prin-
ciple of albumin dialysis, which has been trialled extensively in
patients with ALF and acute-on chronic liver failure (ACLF) but
failed to show a survival benefit [17–19]. Prometheus, which is
based on a similar principle, has been largely trialled in ACLF.
Again, no survival benefit of this device could be demonstrated
[18,20]. University College London-Liver Dialysis Device
(UCL-LDD) was developed based on the hypothesis that the ‘failure’
of MARS, Prometheus and other such devices may be partly due to
their inability to reduce activation of the innate immune system
[21,22] and their inability to restore the function of circulating
albumin molecules retained within the patient [7,8,23].
UCL-LDD is a novel artificial extracorporeal liver assist device,
which includes a high cut-off filter for extraction of albumin,
along with bound toxins, by haemofiltration and a selective endo-
toxin adsorption cartridge for selective endotoxin extraction by
haemoperfusion. We hypothesised that UCL-LDD in combination
with HSA infusion would prolong survival in ALF, not only by
removal of water soluble and protein bound toxins, but also by
selective reduction in endotoxemia, improvement in albumin
detoxifying function and reduction in the innate immune
response. Our aim was to interrogate our hypothesis by testing
the effects of UCL-LDD compared to a Control Device delivering
standard continuous renal replacement therapy in an
APAP-induced porcine model of ALF.Journal of Hepatology 201Material and methods
Porcine model of acute liver failure (PALF)
A previously described pig model of APAP-induced ALF (PALF) was used in this
study and has been described elsewhere [24]. Female, 26–36 kg, Landrace cross
Large White pigs were used and all animal procedures complied with the animals
(Scientific Procedures) Act 1986. Briefly, pigs were maintained under general
anaesthesia with intermittent positive pressure ventilation. Pigs were instru-
mented for intravenous fluid and drug administration; arterial and venous blood
sampling; and continuous monitoring of intracranial pressure (ICP), central
venous pressure (CVP), direct arterial blood pressure, cardiac output and urine
output. Critical care protocols for intravenous fluid therapy and maintenance of
acid-base status, electrolyte balance, normoglycaemia, cardiovascular function
and respiratory function were adhered to in order to maintain pre-defined phys-
iological targets, detailed in Supplementary material [24]. However, albumin
infusion was used according to a fixed protocol (see below).
Acute liver failure was induced in ‘APAP pigs’ with an aqueous APAP suspen-
sion, given via an oroduodenal tube. A loading dose of 0.25 g/kg APAP was fol-
lowed by an hourly maintenance APAP dose, adjusted between 0.5 and 4 g to
achieve toxic serum APAP concentrations of greater than 300 mg/L. APAP dosing
was discontinued once the International Normalised Ratio (INR) exceeded three
and this time point is hereafter referred to as ‘ALF’. This value was chosen as,
in the PALF model, an INR of three is associated with 100% mortality.
Thereafter, APAP pigs were treated with UCL-LDD or a ‘Control Device’ (CD) until
non-recoverable cardiorespiratory arrest or 20 h after ALF. At 20 h after ALF, sur-
viving animals were terminated with sodium pentobarbitone. ‘Control pigs’ were
administered water without APAP for 20 h and then supported for a further 20 h
prior to termination with sodium pentobarbitone. The 20 h end point was a
requirement of the local ethics and welfare committee.
For survival studies, ‘‘death’’ was defined as time of non-recoverable car-
diorespiratory arrest or when at least two of the following criteria were met:
haematocrit <10%; blood potassium >5.5 mmol/L; blood lactate >10 mmol/L;
blood pH <7.25; partial pressure of oxygen in arterial blood (PaO2) <60 mmHg.
These alternative parameters for ‘‘death’’ were based on pilot study data, which
showed that cardiorespiratory arrest always occurred within 1 to 3 h of occur-
rence of two of these parameters and that use of these terminal phase criteria
to define death reduced variability in survival times and therefore number of pigs
required for survival studies.
UCL-LDD
All equipment and consumables were obtained from Gambro Dialysatoren
GmbH, Rostock, Germany and used following the recommendations of this com-
pany. UCL-LDD incorporated two haemofilters: ‘SepteX’, a high cut-off filter for
extraction of albumin, along with bound toxins, by haemofiltration and ‘OXiris’,
a selective endotoxin adsorption cartridge for selective endotoxin extraction by
haemoperfusion. Details of the UCL-LDD device are described in Supplementary
material. UCL-LDD was compared to CD in which the two haemofilters of the
UCL-LDD were replaced with standard continuous renal replacement
haemofilters.
Albumin infusion
In early pilot experiments, a marked reduction in serum albumin concentrations,
to values less than 10 g/L, were detected in pigs treated with APAP, likely due to
excessive capillary leak in this species [24]. Hence a fixed protocol for albumin
infusion was developed as part of the PALF model to compensate for this. At onset
of APAP dosing, intravenous infusion of 20% HSA (Bio Products Laboratory Ltd,
Hertfordshire, UK) was initiated at 1.6 g albumin/h, this was increased 12 h later
to 16 g albumin/h and further increased at ALF to 20 g albumin/h. Control pigs
were given 1.6 g albumin/h from onset of water (placebo) administration. In both
APAP and Control pigs, two units of porcine fresh frozen plasma were given at ALF
or equivalent in order to prevent bleeding. After onset of device treatment in
APAP pigs albumin infusion was discontinued if serum albumin exceeded
20 g/L. This albumin infusion protocol ensured appropriate (targeted to serum
albumin concentrations) albumin replacement with UCL-LDD treatment.
Study plan
Two studies, a pilot and main study, were performed sequentially.5 vol. 63 j 634–642 635
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Pilot study. Efficacy of endotoxin and albumin removal by UCL-LDD
The pilot study determined whether the two filters could be used together and
also to assess whether the individual filters were able to successfully (1) remove
endotoxin resulting in a lowering of plasma endotoxin concentrations in the ani-
mals and (2) filter albumin and achieve an improvement in albumin function. The
data for this pilot experiment is described in Supplementary material.
Main study. Effect of UCL-LDD treatment on progression of ALF
To determine the effect of UCL-LDD treatment on survival, clinical progression,
innate immune response and hepatocyte necrosis in APAP pigs following onset
of ALF, 22 pigs were randomly allocated to one of three treatment groups: 1) nine
pigs to the ‘‘APAP-UCL-LDD’’ group, induced to ALF with APAP and treated with
UCL-LDD; 2) nine pigs to the ‘‘APAP-CD’’ group, induced to ALF with APAP and
treated with CD; and 3) four pigs to the ‘‘Control-CD’’ group, sham induction to
ALF with water and treated with CD. Number of pigs used was determined by
power analysis to detect a 30% or greater increase in survival in APAP pigs with
UCL-LDD compared to CD (5% type I error rate, 80% power). Extracorporeal device
treatment was initiated 2 h after ALF. All researchers except one were blinded to
the device being used. The researcher with knowledge of the device set up the
device, concealing the cartridges and managed the study from the point of ALF
to initiation of device treatment. All subsequent care of the model was carried
out by blinded researchers. Clinical, biochemical and histopathological progres-
sion of disease was monitored as described previously [24]. Plasma (heparin)
samples were collected before onset of APAP dosing, at ALF and every four hours
thereafter and stored at 70 C pending analysis.
Kinetic turbidimetric limulus amebocyte lysate assay for endotoxin
Plasma endotoxin concentrations were measured using the Kinetic Turbidimetric
Limulus Amebocyte Lysate Assay (Charles River Laboratories International Inc.,
MA, USA) according to the manufacturer’s instructions and as described previ-
ously [25].
High performance liquid chromatography for HMA, HNA-1 and HNA-2
High performance liquid chromatography (JASCO UK Ltd, Essex, UK), using the
Shodek Asahipak ES-502N 7C ion exchange column (Thames Restek UK Ltd,
Buckinghamshire, UK), was used to determine the percentage of HSA present as
the non-oxidised human mercaptalbumin (HMA) capable of free radical scaveng-
ing and molecule binding; the reversibly oxidised human non-mercaptalbumin-1
(HNA-1) and the irreversibly oxidised human non-mercaptalbumin-2 (HNA-2) in
plasma samples, as previously described [8]. Albumin fractions were expressed as
a percentage of the area under each peak relative to the total area under all three
peaks using EZChrom Elite software (Agilent Technologies UK Ltd, Berkshire, UK).
TLR4 and IL-18/IL-1b reporter cell assays
Systemic activation of the TLR4 signalling pathway and presence of bioactive
IL-18 and IL-1b in plasma samples was assessed using ‘HEK-Blue hTLR4’ cells
and ‘HEK-Blue IL-18/IL-1 b’ cells (InvivoGen, California, USA), respectively,
according to the manufacturer’s instructions, as described previously [26] and
detailed in Supplementary material.
Total HMGB1 ELISA
Total HMGB1 in plasma sampleswas quantified by enzyme-linked immunosorbent
assay (ELISA, Shino-Test Corporation, Tokyo, Japan) as previously described [10].
Statistical analysis
Recordings of anaesthetic monitor data and drug and fluid infusion rates were
recorded every 15 min, arterial blood gas data every hour, INR every one to four
hours and biochemical analyses every four hours. Hourly to four hourly group
summaries for each group (APAP-UCL-LDD, APAP-CD and Control-CD) were
expressed as mean ± standard error and assessed graphically. To compare pro-
gression to ALF between the two APAP groups and the Control-CD group, linear
mixed effects models and the two sample t-test were used. To assess the effect
of UCL-LDD, group comparisons between APAP-UCL-LDD and APAP-CD were636 Journal of Hepatology 201made for the first 8 h of treatment i.e. ALF + 2 h to ALF + 10 h. First degree
auto-regressive or compound symmetry (co)variance structure was used to
account for the correlation between hourly or 4-hourly repeated measures.
These analyses were carried out using the generalised linear and mixed model
procedures in SAS version 9.1 for PC (Copyright, SAS Institute Inc. Cary, NC,
USA) and significance was set at the 5% level.
Assay results for endotoxin, redox states of albumin, systemic TLR4 activity,
bioactive IL-18/IL-1 b and HMGB1 were available up to every 4 h from point of
ALF. For endotoxin, redox states of albumin and HMGB1 assays, it was not possi-
ble to run samples from all animals in each group: for these assays, animals
included were based on a randomised block design, dependent on the three study
groups and number of samples which could be included in each assay plate. To
assess the effect of APAP and treatment, group comparisons between
APAP-UCL-LDD, APAP-CD and Control-CD were made. First degree
auto-regressive or compound symmetry (co)variance structure was used to
account for the correlation between repeated measures. Analyses were carried
out using the generalised linear and mixed model procedures in SAS version
9.1 for PC (Copyright, SAS Institute Inc. Cary, NC, USA) and significance was set
at the 5% level.
To compare survival time between APAP-UCL-LDD and APAP-CD, Cox
regression and Kaplan-Meier survival curve analyses were performed using R
3.0.0 (Institute for Statistics and Mathematics, Wirtschaftsuniversität, Vienna,
Austria).Results
Survival
All nine APAP-UCL-LDD pigs, seven out of nine APAP-CD pigs and
all four Control-CD pigs completed the study. Two APAP-CD pigs
were excluded due to early achievement of ALF criteria at 12.5
and 13 h after onset of APAP dosing, more than 30% below the
mean of 19.3 ± 1.8 expected for the PALF model. In the nine
APAP-UCL-LDD pigs and seven APAP-CD pigs that completed
the study mean serum APAP concentrations exceeded 300 mg/L
within 4 h of onset of APAP dosing and INR >3, ALF, was recorded
at 18.4 ± 0.6 h. Total dose of acetaminophen administered to
achieve ALF was 50.7 ± 3.0 g and 49.2 ± 4.0 g in the APAP-CD
and APAP-UCL-LDD groups respectively.
All APAP-CD pigs progressed to ‘‘death’’ within the 20 h study
period from ALF, with a median survival time from ALF of 12 h
(range 11–17 h). In the APAP-CD group ‘‘death’’ was achieved in
five by cardiorespiratory arrest and in two by achievement of
two ‘‘death’’ criteria: blood pH <7.25 with haematocrit <10% in
one pig and blood pH <7.25 with lactate >10 mmol/L and haema-
tocrit <10% in one pig. Three out of nine APAP-UCL-LDD pigs ‘‘sur-
vived’’ to the end of the study, resulting in an overall estimated
median survival time from ALF for APAP-UCL-LDD pigs of 15 h
(range 9–20 h). In the APAP-UCL-LDD group, ‘‘death’’ was
achieved in one by cardiorespiratory arrest and in five by
achievement of two ‘‘death’’ criteria: blood pH <7.25 with one
or more of haematocrit <10%, blood potassium >5.5 mmol/L and
blood lactate >10 mmol/L. Therefore UCL-LDD resulted in a 67%
reduced risk of ‘‘death’’ compared to CD (hazard ratio = 0.33,
p = 0.0439, Fig. 1).
Liver, cerebral and renal function
Acute centrilobular to midzonal hepatocyte degeneration and
necrosis was confirmed at post mortem examination in all
APAP pigs. All Control-CD pigs had normal livers. Necrosis was
graded as mild, moderate or severe according to percentage of
parenchyma affected: there was no significant difference in
severity of necrosis between UCL-LDD and CD (Supplementary5 vol. 63 j 634–642
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Fig. 1. UCL-LDD reduces risk of death in ALF. Effect of UCL-LDD (solid black line)
on survival compared to CD (broken black line).
JOURNAL OF HEPATOLOGYmaterial 5). Elevation in liver enzymes, aspartate amino trans-
ferase (AST) and alkaline phosphatase (ALP), was not seen in this
animal model of ALF as reported previously (Table 1) [24].
Intracranial pressure increased significantly from onset of ALF
to death from 17 ± 1 to 32 ± 1 mmHg (p <0.0001) in the
APAP-UCL-LDD group and from 16 ± 2 to 33 ± 3 mmHg
(p <0.0001) in the APAP-CD group. This change was not signifi-
cantly different between groups.
Serum creatinine was significantly higher in the APAP groups
compared to the Control-CD group at ALF (Table 1, p = 0.0004).
During the following 10 h there was a mild decrease in creatinine
concentrations in both APAP-UCL-LDD and APAP-CD groups
(p = 0.0237), but with no significant difference between devices.
Post mortem kidney examination revealed varying degrees of
tubular epithelial cell swelling and protein loss in both theTable 1. Kidney and liver biochemistry profiles.
Time following
onset of ALF (h)
Group Albumin
(g/L)
Urea
(mmo
ALF APAP-UCL-LDD (n = 8) 15 ± 1 5 ± 1
APAP-CD (n = 7) 13 ± 1 4 ± 1
Control-CD (n = 4) 33 ± 3 3 ± 1
ALF + 4 h APAP-UCL-LDD (n = 9) 15 ± 1 4 ± 1
APAP-CD (n = 7) 15 ± 1 3 ± 1
Control-CD (n = 4) 33 ± 3 3 ± 1
ALF + 8 h APAP-UCL-LDD (n = 9) 17 ± 1 4 ± 1
APAP-CD (n = 6) 17 ± 1 3 ± 1
Control-CD (n = 3) 30 ± 4 3 ± 1
ALF + 12 h APAP-UCL-LDD (n = 8) 20 ± 2 3 ± 1
APAP-CD (n = 5) 18 ± 2 3 ± 1
Control-CD (n = 4) 30 ± 2 2 ± 1
ALF + 16 h APAP-UCL-LDD (n = 5) 24 ± 2 108 ±
APAP-CD - -
Control-CD (n = 3) 29 ± 2 43 ± 
ALF + 20 h APAP-UCL-LDD (n = 4) 27 ± 3 105 ±
APAP-CD - -
Control-CD (n = 4) 30 ± 1 43 ± 
4 h time point 
preceding death
APAP-UCL-LDD (n = 8) 22 ± 2 3 ± 1
APAP-CD (n = 6) 19 ± 3 3 ± 1
Control-CD (n = 4) 30 ± 1 2 ± 1
Kidney and liver biochemistry profiles in APAP-UCL-LDD, APAP-CD and Control-CD group
denotes insufficient sample number for comparison due to death).
Journal of Hepatology 201APAP-UCL-LDD and APAP-CD groups, but no renal pathology in
the Control-CD group.
Cardiovascular function
During the first 8 h of device treatment, both APAP groups
demonstrated: peripheral vasodilation (hypotension, p <0.0001)
with low systemic vascular resistance index (SVRI, p <0.0001);
tachycardia (p <0.0001); a high cardiac output failure state [in-
creased cardiac index (CI, p = 0.0069), stroke volume index (SVI,
p <0.0001), left ventricular stroke work index (LVSWI,
p = 0.0164) and right ventricular stroke work index (RVSWI,
p <0.0001)]; and elevation in CVP (p <0.0001) and pulmonary
capillary wedge pressure (PCWP, p = 0.0011) associated with
development of peripheral oedema. In the APAP-UCL-LDD group,
development of systemic vasoplegia, high cardiac output and
hyperdynamic circulatory state was less severe and colloid
requirements were lower compared to the APAP-CD group.
These differences were significant after 8 h of device treatment
(Fig. 2).
Respiratory function
During the first 8 h of device treatment, both APAP groups
demonstrated an increasing requirement for mechanical ventila-
tor support to achieve control of minute ventilation, PaCO2 and
oxygenation (Fig. 3). This increasing requirement was delayed
in the APAP-UCL-LDD group compared to the APAP-CD group,
resulting in significantly higher lung compliance (Compliance), 
/L)
Creatinine 
(μmol/L)
Total bilirubin 
(μmol/L)
AST 
(U/L)
ALP 
(U/L)
117 ± 7 6 ± 1 33 ± 4 62 ± 5
118 ± 10 5 ± 1 29 ± 4 47 ± 3
67 ± 4 6 ± 1 56 ± 7 113 ± 21
108 ± 5 5 ± 1 45 ± 4 51 ± 2
113 ± 9 5 ± 1 41 ± 4 42 ± 4
64 ± 8 10 ± 2 99 ± 10 103 ± 14
107 ± 5 6 ± 1 49 ± 8 54 ± 6
110 ± 8 5 ± 1 43 ± 5 39 ± 6
56 ± 13 10 ± 4 88 ± 16 85 ± 13
107 ± 6 7 ± 1 57 ± 6 63 ± 8
119 ± 9 5 ± 1 53 ± 11 39 ± 6
48 ± 7 7 ± 1 84 ± 10 92 ± 12
 4 108 ± 4 9 ± 1 84 ± 14 84 ± 9
- - - -
9 43 ± 9 6 ± 1 74 ± 6 82 ± 13
 2 105 ± 2 10 ± 1 107 ± 24 94 ± 23
- - - -
5 43 ± 5 6 ± 1 70 ± 4 86 ± 11
100 ± 5 8 ± 1 73 ± 14 67 ± 9
116 ± 8 6 ± 1 63 ± 20 40 ± 6
43 ± 5 6 ± 1 70 ± 4 86 ± 11
s at ALF, every 4 h thereafter and at the 4 h time point directly preceding death. (‘-’
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Fig. 2. UCL-LDD improves cardiovascular function in ALF. UCL-LDD delayed vasoplegia/high output cardiac failure and reduced severity of cardiovascular failure during
the first 8 h of treatment i.e. 2–10 h after ALF (blue shading) in the APAP-UCL-LDD group (solid black line) compared to APAP-CD Group (broken black line) [Control-CD
Group (grey line)]. (ALF, time INR exceeded 3; MAP, mean arterial pressure; HR, heart rate; SVRI, systemic vascular resistance index; CI, cardiac index; SVI, stroke volume
index; LVSWI, left ventricular stroke work index; RVSWI, right ventricular stroke work index; Voluven, colloid therapy; ⁄, significant (p <0.0500) difference between APAP-
UCL-LDD and APAP-CD).
Research Articlelower respiratory rate (RR) and lower inspiratory pressures (Pinsp)
8 h after onset of device treatment (Fig. 3).
Endotoxin removal and albumin exchange
Endotoxin removal by UCL-LDD resulted in a reduction in
increase in plasma endotoxin concentrations from ALF to death
in the APAP-UCL-LDD group (57.3 ± 15.2% increase) compared
to the APAP-CD group (119.3 ± 13.8% increase) (p = 0.024) (Fig. 4).
Serum albumin concentration was significantly lower in both
APAP groups compared to Control-CD (p <0.0001) at ALF and during
the following 12 h. However there was no significant difference in
serum albumin concentrations between APAP-UCL-LDD and
APAP-CD groups during this time period (Table 1). Total albumin
dose administered up to ALF was 126 ± 14 g, 129 ± 8 g and
32 ± 0 g in APAP-UCL-LDD, APAP-CD and Control-CD groups respec-
tively. Total albumin dose administered during the first 12 h after
ALF, which included the first 10 h of device treatment, was 240 g
for both APAP-UCL-LDD and APAP-CD groups and 19.2 g for the
Control-CD group. Six and 10 h after onset of device treatment, per-
centage of serum albumin present in the HNA-2 form was signifi-
cantly lower in the APAP-UCL-LDD group compared to the
APAP-CD group (p = 0.023 and p = 0.046 respectively, Table 2).
Activation of the TLR4 signalling pathway and IL-18/IL-1b bioactivity
Activation of TLR4 signalling in the reporter cell lines was
observed with plasma from both APAP groups. In the APAP-CD638 Journal of Hepatology 201group this activation became significant at 12 h after onset of
ALF (p = 0.040, Fig. 5). However in the APAP-UCL-LDD group,
UCL-LDD treatment delayed activation of the TLR4 signalling
pathway to 20 h after onset of ALF i.e. 18 h after onset of
UCL-LDD treatment (p = 0.030, Fig. 5).
No significant IL-18/IL-1b bioactivity was detected in any of
the plasma samples obtained after onset of ALF from animals in
the APAP-CD and APAP-UCL-LDD groups when compared to ani-
mals in the Control-CD group (Supplementary material).
Total HMGB1 plasma concentrations
There was no significant change in total HMGB1 plasma concen-
tration in the Control-CD group with time. In the APAP-CD and
APAP-UCL-LDD groups, total HMGB1 plasma concentration
increased significantly with progression of ALF to death
(p <0.001) with no significant differences between groups (Fig. 6).Discussion
This study shows that UCL-LDD, an extracorporeal liver assist
device, combined with HSA infusion is able to attenuate increase
in circulating endotoxin concentrations, effect albumin exchange
and decrease percentage of circulating HNA-2 in PALF. By so
doing, UCL-LDD prolongs survival in ALF, associated with attenu-
ation in the development of circulatory failure and acute lung
injury. This clinical improvement is associated with a delay in5 vol. 63 j 634–642
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Fig. 4. UCL-LDD reduces endotoxaemia in ALF. Endotoxin concentrations
measured in plasma samples from APAP-CD, APAP-UCL-LDD and Control-CD pigs
at time zero (0 h), ALF, ALF + 4 h, ALF + 8 h and the last blood sampling point prior
to death (‘Terminal’). All plasma samples were diluted 1 in 10 and spiked with
5EU endotoxin. Endotoxin concentrations at ALF + 8 h (*p = 0.018) and ‘Terminal’
(**p = 0.002) were significantly lower in the APAP-UCL-LDD group compared to
the APAP-CD group.
JOURNAL OF HEPATOLOGYsystemic activation of the TLR4 signalling pathway. Adverse clin-
ical effects were not seen compared to standard continuous renal
replacement therapy. The survival benefit and lack of adverse
effects would support clinical trials of UCL-LDD in ALF patients.
Artificial extracorporeal liver support devices, with the pri-
mary aim of replacing the detoxifying functions of the liver, have
been in development since the 1950’s [27], but an improvement
in survival of liver failure patients with these devices has
remained elusive [17,19,20,28]. The specific design criteria for
UCL-LDD compared to previous liver dialysis devices were not
only to achieve non-selective removal of water soluble and pro-
tein bound toxins, but also selective reduction in endotoxaemia
and albumin replacement, in order to improve albumin detoxify-
ing function and reduce the innate immune response. These cri-
teria were based on a number of observations in liver failure
patients: 1) irreversible loss of the detoxifying function of albu-
min in ACLF [7,8]; 2) significant association between loss of albu-
min function and mortality risk in ACLF [7,8]; 3) significant
association between infection/endotoxaemia and morbidity and
mortality in ACLF and ALF [29–31]; and 4) increasing evidenceJournal of Hepatology 201to support the role of endotoxin in the innate immune response
in ALF, which worsens liver injury and clinical liver failure
[14,15,26]. In keeping with the hypothesis, treatment was associ-
ated with a survival advantage in ALF pigs. However, due to the
pre-determined termination of all studies 20 h after ALF, it is
not possible to say whether UCL-LDD treatment may have per-
mitted recovery in those animals that ‘survived’. From the clinical
perspective this survival advantage was due to the effect of the
device on cardiac and pulmonary function rather than improve-
ment in intracranial hypertension or liver necrosis. Failure to
demonstrate improvement in liver necrosis is not surprising as
treatment with UCL-LDD was initiated when ALF was fully
established.
The potential role of various continuous renal replacement
therapy techniques to reduce the innate immune response in crit-
ically ill patients has been widely studied in sepsis and systemic
inflammatory response syndrome (SIRS) [32]. Indeed both of the
haemofilters incorporated within UCL-LDD have been investi-
gated in sepsis and SIRS.
In this study, the filter, SepteX, employed to achieve removal
of albumin and albumin bound toxins, has a nominal cut-off of
60 kDa. However, in vitro and in vivo studies have demonstrated
albumin (64 kDa) losses with this filter [33,34]. The albumin loss
of 2.4 g/h in the current study is in line with these previous
reports. However SepteX was actually designed for removal of
pro and anti-inflammatory cytokines up to 45 kDa in states of
excessive inflammation. In septic patients with acute renal fail-
ure, SepteX has been shown to decrease plasma concentrations
of IL-6 and IL-1 receptor antagonist (IL-1ra), correct immune dys-
function and reduce the need for vasopressor support compared
to standard renal replacement therapies [35–37]. Therefore the
beneficial effect of SepteX in UCL-LDD may be due to removal
of dysfunctional albumin, but also dampening of the innate
immune response implicated in ALF.
UCL-LDD treatment plus HSA infusion was associated with a
significant decrease in the irreversibly destroyed form of albu-
min, the HNA-2 form. The decrease reported was of the order
of magnitude previously demonstrated to be prognostic for5 vol. 63 j 634–642 639
Table 2. Change in percentage of human albumin present as HMA, HNA-1 and HNA-2 with time at ALF and times after onset of device treatment in the APAP-UCL-
LDD and APAP-CD groups.
Duration of device treatment (h) Group HMA (%) HNA-1 (%) HNA-2 (%)
ALF before onset of device treatment APAP-UCL-LDD (n = 5) 41.6 ± 7.1 46.4 ± 7.0 11.8 ± 1.4
APAP-CD (n = 5) 34.8 ± 8.5 52.4 ± 9.8 12.6 ± 2.2
2 h APAP-UCL-LDD (n = 5) 53.8 ± 2.1 33.6 ± 1.8 12.6 ± 1.2
APAP-CD (n = 5) 45.8 ± 1.6 38.2 ± 2.1 16.0 ± 1.1
6 h APAP-UCL-LDD (n = 4) 60.0 ± 2.5 30.2 ± 1.7 10.0 ± 1.7
APAP-CD (n = 4) 51.5 ± 2.0 32.5 ± 1.3 16.0 ± 2.1
(p = 0.023)
10 h APAP-UCL-LDD (n = 5) 65.8 ± 1.7 22.6 ± 1.2 11.4 ± 0.9
APAP-CD (n = 4) 57.8 ±4.9 25.8 ± 3.4 16.5 ± 1.8
(p = 0.046)
Device treatment was started 2 h after onset of ALF. p values are for comparisons between APAP-UCL-LDD and APAP-CD and are given where p <0.050.
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Fig. 5. UCL-LDD delays activation of the TLR-4 signalling pathway in ALF.
Response ratios (relative to negative control) for TLR4 reporter cell assay.
Response ratio for positive control was 3.196 ± 0.369. Response ratio for APAP-CD
was only significantly increased compared to Control-CD at ALF + 12 h
(*p = 0.040). Response ratio for APAP-UCL-LDD was only significantly increased
compared to Control-CD at ALF + 20 h (**p = 0.030), representing a delay in TLR4
activation by UCL-LDD treatment.
Research Articlepatients with advanced liver disease [8]. It is likely that the
reduction in HNA-2 resulted from removal of HNA-2 by SepteX
and replacement with non-oxidised albumin. In addition,
improvement in systemic oxidative stress by UCL-LDD may have
resulted in decreased oxidative albumin damage. Improvement
in albumin function, clearance of albumin bound toxins and640 Journal of Hepatology 201consequent reduction in toxin-associated tissue injury likely con-
tributed to improved survival.
The selective endotoxin adsorption filter, OXiris was used
with SepteX in UCL-LDD, as our preliminary data clearly demon-
strate that OXiris alone inhibited progression of endotoxaemia in
ALF, but that SepteX alone did not. Oxiris has been shown previ-
ously in a pig model of sepsis to decrease plasma IL-6 concentra-
tions and improve cardiovascular function [38] in agreement
with the data presented in the current study.
Cell response assays were used to assess innate immune cell
activation in this study, as they may more accurately reflect the
balance of pro and anti-inflammatory mediators within the
plasma compared to the measurement of individual cytokine
concentrations. Numerous studies have demonstrated that cer-
tain renal replacement therapies result in significant cytokine
clearance, associated with clinical improvement in critical illness,
without significant effect on circulating cytokine concentrations,
which may be due to reductions in tissue level concentrations of
pro and anti-inflammatory mediators and a return to near normal
immune homeostasis at the tissue level [38]. In this study we
document delay in systemic activation of the TLR4 signalling
pathway in ALF by UCL-LDD treatment, which concurrently
attenuates rise in endotoxaemia and improves clinical signs of
systemic inflammation. This agrees with data from rodent mod-
els which suggest that endotoxin activates cellular receptors
including TLR4 on hepatic Kupffer cells to exacerbate
APAP-induced liver injury and clinical liver failure [14,15,26].
However the current study does not provide a direct assessment
of innate immunity within the liver. Future studies to explore the
mechanisms underlying the beneficial effect of UCL-LDD should
focus on the liver, using techniques such as microdialysis [39].
The finding that CD and UCL-LDD treatment did not decrease
total HMGB1 plasma concentrations was unexpected. Previous
studies show that filtration with a high cut-off membrane, may
not achieve HMGB1 clearance [40]. However AN69 ST, a mem-
brane similar to OXiris, was able to achieve 100% HMGB1 clear-
ance in vitro by adsorption [40]. HMGB1 exists in a number of
isoforms with post-translational modifications governing subcel-
lular localisation and release from cells and inflammatory func-
tion [41–44]. It is possible, that in this study, improved survival
was associated with selective removal of a specific functionally
relevant HMGB1 isoform, which was not reflected in total
HMGB1 plasma concentration. Mass spectrometry based profiling
of HMGB1 isoforms would be useful to investigate this further.5 vol. 63 j 634–642
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Conclusion
In a pig model of APAP-induced ALF, we have shown that
UCL-LDD, a novel extracorporeal liver assist device, in combina-
tion with HSA infusion, results in a decrease in circulating irre-
versibly oxidised albumin (HNA2) and a reduction in the
overall severity of endotoxaemia. This attenuated the severity
of multi-organ dysfunction, resulting in prolonged survival and
an estimated 67% reduced risk of death compared to controls,
associated with a delay in systemic activation of the TLR4 sig-
nalling pathway. No adverse effect of the device or compatibility
issues were observed providing rationale for clinical trials of this
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